NasdaqGM:KROSBiotechs
Keros Therapeutics (KROS): Valuation Check After Sharp Share Price Rebound and Ongoing Revenue Contraction Forecasts
Keros Therapeutics (KROS) has suddenly jumped about 30% over the past month, drawing fresh attention just as Wall Street is bracing for roughly 40% annual revenue contraction over the next few years.
See our latest analysis for Keros Therapeutics.
The latest burst of buying has pushed Keros Therapeutics’ share price to 21.69, with a 30 day share price return of roughly 34% and a 90 day gain near 38%. However, the 1 year total shareholder return is still deep in negative territory. This...